Home > Insider Trading > Filing (0001415889-24-029143)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1907108	Lexeo Therapeutics Inc.	LXEO	Biological Products, (No Disgnostic Substances) (2836)	854012572

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1995218	Nolan Richard Townsend	C/O Lexeo Therapeutics, Inc. 345 Park Avenue South, Floor 6 New York NY 10010	Chief Executive Officer	No	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2024-12-10	2,500	$2.33	123,195	No	4	M	Direct
Common Stock	Disposition	2024-12-10	2,500	$8.20	120,695	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (right to buy)	Disposition	2024-12-10	2,500	$0.00	2,500	$2.33

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
118,655		2031-02-15	No	4	M	Direct

Footnotes

The exercises and sales in this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2023.
This transaction was executed in multiple trades at prices ranging from $7.98 to $8.54. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Includes 43,750 restricted stock units (RSU's). Each RSU represents a contingent right to receive one share of Common Stock, subject to the applicable vesting schedule and conditions of each RSU.
25% of the shares underlying the option vested on November 21, 2021, and 1/48th of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service.